France Hemodialysis Vascular Grafts Market Analysis

France Hemodialysis Vascular Grafts Market Analysis


$ 3999

France Hemodialysis Vascular Grafts Market was valued at $5.76 Bn in 2023 and is predicted to grow at a CAGR of 4.1% from 2023 to 2030, to $7.63 Bn by 2030. The key drivers of this industry include the rising prevalence of diabetes and hypertension, the aging population, and technological advancements. The industry is primarily dominated by W. L. Gore, C. R. Bard, Vascudyne, and LeMaitre among others.

ID: IN10FRMD026 CATEGORY: Medical Devices GEOGRAPHY: France AUTHOR: Sarita Yadav

Buy Now

France Hemodialysis Vascular Grafts Market Executive Summary

France Hemodialysis Vascular Grafts Market was valued at $5.76 Bn in 2023 and is predicted to grow at a CAGR of 4.1% from 2023 to 2030, to $7.63 Bn by 2030.

Hemodialysis vascular grafts are specialized devices crucial for establishing vascular access in patients, particularly those with end-stage renal disease (ESRD) undergoing hemodialysis. These grafts function as conduits, linking an artery to a vein to facilitate blood movement to and from the dialysis machine during treatment. They are designed to provide durable and reliable access, replacing or augmenting natural blood vessels that may not withstand the frequent punctures required in dialysis sessions. Common types include synthetic grafts made from materials like polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE), and biological grafts derived from treated animal tissue. Surgical implantation involves connecting the graft in the arm or leg, ensuring proper placement and meticulous care to maintain sufficient blood flow and mitigate complications such as infection or clotting.

In France, chronic kidney disease (CKD) is prevalent, particularly in older age groups, with CKD stage 3–5 affecting between 4.83% and 4.98% of the population and an annual incidence rate of 0.49%. Women tend to have a higher prevalence of CKD compared to men across different age groups. End-stage kidney disease (ESKD) necessitating renal replacement therapy (RRT) is significant in Europe, including France, where 83,311 individuals initiated RRT in 2016. By the end of that year, the total number of individuals requiring RRT reached 564,638, with over 80% receiving hemodialysis (HD) as the primary treatment modality.

The market therefore is driven by significant factors like the rising prevalence of end-stage renal diseases, government investment in healthcare, and technological advancements. However, cost control measures, risk of complications, and competitive from alternatives restrict the growth and potential of the market.

Prominent players in this field are W. L. Gore who offers the PROPATEN graft with a special heparin surface to fight clotting and the ACUSEAL graft designed for early use after implantation and C. R. Bard provides traditional ePTFE grafts and the innovative Vectra graft made from a different material that may allow for quicker access compared to standard options. Other contributors include Vascudyne, Inc., and LeMaitre among others.

France Hemodialysis Vascular Grafts Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Rising prevalence of End-Stage Renal Disease (ESRD): France has high prevalence of diabetes and hypertension, both significant risk factors for ESRD. According to the French Renal Network (RESAN), over 73,000 people in France were receiving renal replacement therapy (including hemodialysis) in 2021. The increasing ESRD population will require consistent hemodialysis treatment, driving the demand for vascular grafts to create access points for blood flow.

Government Investment in Healthcare:  France has a universal healthcare system that covers a significant portion of the costs associated with hemodialysis treatment, including vascular graft procedures. This financial support facilitates patient access to these procedures.

Technological Advancements:  Development of new graft materials and designs with improved patency rates (ability to remain open for blood flow) and lower infection risks can make hemodialysis procedures more efficient and encourage their use.

Market Restraints

Risk of Complications: Complications associated with hemodialysis vascular grafts, such as infections or thrombosis, deter their use. These risks affect patient outcomes and impact the acceptance of grafts in clinical practice.

High Cost of Vascular Grafts: The high cost of advanced hemodialysis vascular grafts is a significant barrier to widespread adoption. Expensive grafts limit access for some patients and healthcare facilities, affecting overall market growth.

Competition from Alternative Therapies: The availability of alternative dialysis options, such as peritoneal dialysis, provides competition for hemodialysis vascular grafts. Some patients and providers opt for these alternatives based on preference or clinical suitability.

Regulatory Landscape and Reimbursement Scenario

In France, the regulatory landscape for hemodialysis vascular grafts is governed by the Agence nationale de sécurité du médicament et des produits de santé (ANSM). ANSM employs a risk-based approach to classify medical devices, with hemodialysis vascular grafts falling under Class IIa (medium risk) or Class III (high risk) based on their design and complexity. To market these grafts in France, compliance with the European Union Medical Device Regulation (MDR) is essential, necessitating a CE marking that confirms adherence to safety and performance standards. The extent of clinical evaluation required varies with the risk classification, with higher-risk devices demanding more comprehensive clinical data to establish safety and efficacy.

France's universal healthcare system significantly subsidizes hemodialysis treatment costs, including procedures involving vascular grafts. The Liste des Produits et Prestations de Santé (LPPS), established by the French Ministry of Health, enumerates reimbursable medical devices and procedures, likely encompassing hemodialysis vascular grafts. Reimbursement rates are negotiated between manufacturers and public health insurance bodies, ensuring transparency and predictability in reimbursement policies, which are vital for market access and manufacturers' financial planning.

Competitive Landscape

Key Players

Here are some of the major key players in the France Hemodialysis Vascular Grafts Market

  • W. L. Gore & Associates, Inc.,
  • C. R. Bard, Inc.,
  • Vascudyne, Inc.,
  • LeMaitre,
  • Getinge AB,
  • Vascular Genesis,
  • InnAVasc Medical, Inc.
  • CryoLife, Inc.
  • Merit Medical Systems
  • Biovic Sdn Bhd.

1. Executive Summary
1.1 Device Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Regulatory Landscape for Medical Device
1.6 Health Insurance Coverage in Country
1.7 Type of Medical Device
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Hemodialysis Vascular Grafts Market Segmentation

Based on Raw Material

  • Polytetrafluoroethylene
  • Polyester
  • Biological materials
  • Polyurethane

Based on Indication

  • Endovascular aneurysm repair
  • Peripheral vascular repair
  • Hemodialysis Access

Based on End-User

  • Hospitals 
  • Clinics
  • Others (Ambulatory surgical centers)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 30 July 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up